First Hip and Knee Surgeries With ARVIS Augmented Reality Navigation System Completed

Seven surgeons in the USA have completed over 30 hip and knee arthroplasty procedures with ARVIS in a range of clinical settings.

Insight Medical Systems reports they have completed the first clinical cases with its ARVIS® wearable augmented reality navigation system in conjunction with DJO’s EMPOWR™ implants. Seven surgeons across the country navigated over 30 total hip and total knee arthroplasties.

“I am so impressed with the accuracy and simplicity of ARVIS and can’t wait to see this technology grow. Having experienced the ups and downs of robotics, Augmented Reality has an endless future improving outcomes in joint arthroplasty in a cost-effective way!” – Robert Limoni, M.D.

“ARVIS was surprisingly easy to incorporate into our surgical workflow. I found it precise and accurate without the tremendous cost and inefficiencies that robotics has introduced to our specialty. Robotics and navigation, as we know it today, will quickly be replaced by this more sophisticated technology.” – Michael Nett, M.D.

This milestone not only emphasizes the value of ARVIS in clinical use, but also the adaptability of this technology to a range of clinical settings. In the last two weeks, ARVIS was used at an orthopedic specialty hospital, community hospitals, large research hospitals, and an ambulatory surgical center (ASC). This list includes sites where the use of computer-assisted surgery is standard, but also facilities that have historically not had access to navigation technology.

“We believe technology should be an integral part of orthopedic surgery, but its benefits shouldn’t be limited to a handful of hospitals that can afford million-dollar robots. It should be accessible to smaller community hospitals and ASC’s where an increasing proportion of elective surgeries are being performed.” – Nick van der Walt, CEO, Insight Medical Systems.

With its proprietary surgical augmented reality eyepiece, ARVIS was designed to be streamlined and cost-effective, making it accessible to any facility where orthopedic surgery is being conducted.

“ARVIS is exciting because it’s computerized navigation that uses the principles of minimalization, accuracy, and currently available equipment (helmets) with minimal footprint in the OR. The navigation camera moves from a large stationary apparatus to be the surgeon. This is the next step we were looking for.” – Ayal Segal, M.D.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”